Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis

Kenji Oritani, Kohshi Ohishi, Shinichiro Okamoto, Keita Kirito, Norio Komatsu, Tetsuzo Tauchi, Hiroshi Handa, Shigeki Saito, Katsuto Takenaka, Kazuya Shimoda, Hikaru Okada, Taro Amagasaki, Shiho Wakase, Kojiro Shimozuma, Koichi Akashi

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Objectives: Myelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality-of-life (QoL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. This study evaluated the effect of ruxolitinib on symptoms and QoL in Japanese patients with MF. Methods: A pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (n=81) was conducted. Changes in total symptom score (TSS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were summarized. Results: Most patients received a starting dose of 15 or 20mg twice daily (BID) and had a final titrated dose of ≥10mg BID. Overall, 67.7% (44/65) achieved a ≥50% reduction from baseline in TSS at week 24. Reductions in TSS were seen in every dose group; the greatest reductions occurred in patients with a final titrated dose of 20 or 25mg BID. Improvements in QoL were seen in patients who achieved a ≥50% reduction in TSS. Generally, improvements in TSS and individual symptoms correlated with reductions in spleen size, with those having a ≥35% reduction in spleen volume having the greatest improvements. Conclusions: Consistent with COMFORT-I, ruxolitinib provided substantial improvements in symptoms and QoL in Japanese patients with MF, with higher doses of ruxolitinib associated with better responses.

Original languageEnglish
Pages (from-to)531-537
Number of pages7
JournalCurrent Medical Research and Opinion
Issue number3
Publication statusPublished - Jan 4 2018

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis'. Together they form a unique fingerprint.

Cite this